title: Cutaneous sarcoidosis and infliximab: evidence for efficacy in refractory disease.
abstract: Biological therapy with tumour necrosis factor alpha antibodies continues to offer a life-changing option for a range of autoimmune and inflammatory skin conditions. We present three cases of sarcoidosis, with refractory cutaneous disease successfully treated with infliximab. A review of the literature shows increased numbers of cases of refractory cutaneous sarcoidosis successfully cleared with infliximab therapy.
authors: Department of Dermatology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
authors: Jenny
authors: J
authors: Tu
authors: Jonathan
authors: J
authors: Chan
mesh_terms: D000368:Aged; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005148:Facial Dermatoses / Q000188:drug therapy; D005260:Female; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use*; D008875:Middle Aged; D019233:Retreatment; D017565:Sarcoidosis, Pulmonary / Q000188:drug therapy*; D012536:Scalp Dermatoses / Q000188:drug therapy; D012871:Skin Diseases / Q000188:drug therapy*
chemical_list: D003879:Dermatologic Agents; D000069285:Infliximab
keywords: cutaneous sarcoidosis; infliximab; quality of life; scarring; tumour necrosis factor